Overview

A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer

Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to compare the severity of ISRs (Injection Site Reactions) following degarelix subcutaneous (s.c.) administrations with two different injection techniques and intramuscular (i.m.) administration in patients with hormone dependent prostate cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Ferring Pharmaceuticals